Journal of Cancer

Research Paper Exosomes from Cancer-associated Fibroblasts Orchestrate Lung Metastasis of Breast Cancer via LncRNA LMAEP Liyan Lao, Huiping Chen, Huiyi Zeng, Penghan Huang, Yufei Chen, Jianing Chen, Wei Wu, Wenfeng Zeng J. Cancer 2026; 17(10): 1783-1796. doi:10.7150/jca.139124 Full text PDF

Research Paper Radiation-induced SLAMF1 reconfigures the SLAM family receptors landscape in triple-negative breast cancer cells Kyung-Hee Song, Jeong-In Park, Seung-Youn Jung, Hong-Jun Park, Jiyeon Ahn, Sang-Gu Hwang, Dae-Seog Lim, Jie-Young Song J. Cancer 2026; 17(10): 1773-1782. doi:10.7150/jca.137668 Full text PDF

Research Paper Per-patient Comparison of [⁶⁸Ga]-FAPI-46 Versus [¹⁸F]FDG as PET Tracers in ER-positive Breast Cancer: Study Design of a Single-centre Prospective Study Melissa Lenaerts, Lisa E.H.W. Duijx, Felix M. Mottaghy, Matthias Bauwens, Robin M.J.M. van Geel, Vivianne C.G. Tjan-Heijnen, Philipp Backhaus, Loes F.S. Kooreman, Patty J. Nelemans, Marjolein L. Smidt, Joachim E. Wildberger, Thiemo J.A. van Nijnatten J. Cancer 2026; 17(10): 1767-1772. doi:10.7150/jca.138448 Full text PDF

Research Paper Prognostic value of neuro-related genes in colorectal cancer and their potential implications for immunotherapy Huantong Wu, Weihua Liu, Shengtao Zhu J. Cancer 2026; 17(10): 1744-1766. doi:10.7150/jca.136690 Full text PDF

Research Paper Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study Okan Aydin, Sermin Dinc Sonusen, Asli Buyukkuscu, Seyyit Bayram Sahin, Serhat Kalkan, Ahmet Emin Ozturk, Mert Erciyestepe, Fatih Atalah, Zehra Sucuoglu Isleyen, Emir Celik, Kayhan Erturk, Muhammed Mustafa Atci J. Cancer 2026; 17(10): 1733-1743. doi:10.7150/jca.138530 Full text PDF

Review Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer Yuan Zhu, Jia Shang, Xin Zhang, Sheng Tu, Gang Li, Shenjuan Li, Hongwei Peng, Haoli Ma, Fangjin Chen, Wan Xiang, Cong Zou, Yu Xiao, Zilin Xu, Kaiyu Qian, Gang Wang J. Cancer 2026; 17(10): 1720-1732. doi:10.7150/jca.138160 Full text PDF

More ...

Issue 9; 2026

Indexed in PubMed and SCI expanded; full texts in Europe PMC. ...

Per-patient Comparison of [⁶⁸Ga]-FAPI-46 Versus [¹⁸F]FDG as PET Tracers in ER-positive Breast Cancer: Study Design of a Single-centre Prospective Study

Introduction. [18F]FDG can be considered as PET tracer to determine whole-body staging in patients with locally advanced (LABC), metastatic, and recurrent breast cancer. Yet, previous studies demonstrated a lower amount of metabolic accumulation on [18F]FDG PET in case of oestrogen receptor (ER)-positive breast cancer. Consequently, given the lower metabolic accumulation, patients with ER-positive breast cancer might be at risk for underdiagnosis ...

Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study

Background: The optimal anti-angiogenic strategy in the second-line treatment of metastatic colorectal cancer (mCRC) after progression on first-line FOLFOX plus bevacizumab remains unclear. We aimed to compare the efficacy and safety of FOLFIRI combined with bevacizumab or aflibercept in this well-defined clinical setting. Methods: In this retrospective single-center study, 152 patients with mCRC who progressed after at least four cycles of first-line ...